Key Updates:

  • As a result of a change in the expected timing of release of key clinical effectiveness information, ICER will be removing lecanemab from its upcoming report on Alzheimer’s disease, “Beta-Amyloid Antibodies for Early Alzheimer’s Disease”.  For more information, click here.
  • ICER decided to extend its timeline for assessing beta-amyloid antibodies for early Alzheimer’s disease pending the biologics license application submissions for donanemab (Eli Lilly & Co.) and lecanemab (Eisai Co., Ltd).  The timeline was updated on June 7, 2022. 

Interventions of Interest:

For questions, please contact Kelsey Gosselin, Program Manager, at kgosselin@icer.org.

View the Key Stakeholder List.